Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUVAL vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (mild to moderate),Off-label: management of agitated states or psychiatric conditions (historically)
Hypertension
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
85-90% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.6-1.0 L/kg; indicates extensive extravascular distribution.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 60-70% due to first-pass metabolism.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, dose reduction by 50% is recommended.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Safety and efficacy not established in pediatric patients under 18 years.
Not established; avoid use in children.
Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.,Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.,May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.,Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to rauwolfia serpentina or any component,Active peptic ulcer disease,Ulcerative colitis,History of mental depression, especially with suicidal tendencies,Electroconvulsive therapy (ECT) within 7 days
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No established dose adjustments; use is contraindicated in pregnancy due to known teratogenicity and fetotoxicity.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Rise slowly from sitting or lying down to prevent falls due to low blood pressure.,Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor.,Avoid alcohol, as it may worsen dizziness and drowsiness.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUVAL vs ALDORIL 25, answered by our medical review team.
RAUVAL is a Antihypertensive that works by Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUVAL and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUVAL is: 1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUVAL and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUVAL is classified as Category C. First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairme. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.